Pain Inflammation and Cannabis in HIV

Summary

This study will examine how medical cannabis use affects neuropathic pain, inflammation and adverse events in people living with HIV (PLWH) with neuropathic pain. The investigators will observe how varying ratios of tetrahydrocannabinol (THC) and cannabidiol (CBD) in medical cannabis impact neuropathic pain, inflammation and adverse events.

Conditions

• HIV Infections
• Neuropathic Pain
• Cannabis

Interventions

OTHER

Receipt of Coupon for Placebo Soft-Gel Capsule

The investigators will follow participants who were randomized to receive a coupon for placebo soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study Placebo (0:0) Softgel, 0mg THC and 0mg CBD per cap, Bottle of 30 caps

OTHER

Receipt of Coupon for High THC Soft-Gel Capsule

The investigators will follow participants who were randomized to receive a coupon for high THC soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study Vireo Yellow (6:1) Softgel, 4.29mg THC and 0.72mg CBD per cap, Bottle of 30 caps

OTHER

Receipt of Coupon for Equal THC and CBD Soft-Gel Capsule

The investigators will follow participants who were randomized to receive a coupon for equal THC and CBD soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study Vireo Green (1:1) Softgel, 2.5mg THC and 2.5mg CBD per cap, Bottle of 30 caps

OTHER

Receipt of Coupon for High CBD Soft-Gel Capsule

The investigators will follow participants who were randomized to receive a coupon for high CBD soft-gel capsule medical cannabis products by our collaborators at Vireo medical cannabis dispensary in a separate study Vireo Indigo (1:19) Softgel, 0.25mg THC and 4.75mg CBD per cap, Bottle of 30 caps

Sponsors & Collaborators

• National Institute on Drug Abuse (NIDA)

  collaborator NIH

• University of Colorado, Boulder

  collaborator OTHER

• University of Pittsburgh

  collaborator OTHER

• Vireo Health

  collaborator OTHER

• Montefiore Medical Center

  lead OTHER

Principal Investigators

• Deepika E Slawek, MD, MPH, MS · Montefiore Medical Center

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

100 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-10-28

Primary Completion

2024-05-03

Completion

2024-05-03

Countries

• United States

Study Locations